Related Experiment Video

Updated: Feb 16, 2026

An Ex vivo Model to Study Hormone Action in the Human Breast
12:31

An Ex vivo Model to Study Hormone Action in the Human Breast

Published on: January 8, 2015

12.0K

An Anti-GDNF Family Receptor Alpha 1 (GFRA1) Antibody-Drug Conjugate for the Treatment of Hormone Receptor-Positive

Sunil Bhakta1, Lisa M Crocker2, Yvonne Chen2

  • 1Genentech, Inc., 1 DNA Way, South San Francisco, California. sbhakta@gene.com jagathjr@gmail.com.

Molecular Cancer Therapeutics
|December 29, 2017
PubMed

Insights

Researchers developed a novel antibody-drug conjugate targeting Glial cell line-Derived Neurotrophic Factor (GDNF) Family Receptor Alpha 1 (GFRA1) for Luminal A breast cancer. This targeted therapy demonstrated significant efficacy in preclinical models, offering a promising new treatment avenue.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Luminal A breast cancer, a hormone receptor-positive subtype, accounts for 70% of all breast cancer cases.
  • There is a critical need for targeted therapeutics to improve outcomes for Luminal A breast cancer patients.

Purpose of the Study:

  • To identify and characterize novel antibody-drug conjugates (ADCs) targeting Glial cell line-Derived Neurotrophic Factor (GDNF) Family Receptor Alpha 1 (GFRA1) for Luminal A breast cancer treatment.

Main Methods:

  • Utilized RNA sequencing and immunohistochemistry (IHC) to confirm GFRA1 expression in breast cancer tissues.
  • Developed and tested anti-GFRA1 ADCs with a cleavable valine-citrulline-MMAE (vcMMAE) linker-payload.
  • Evaluated ADC efficacy and pharmacokinetics in vitro, in vivo xenograft models (MCF7, KPL-1), and non-human primates.

Main Results:

  • Confirmed abundant GFRA1 expression in Luminal A breast cancer tissues, with minimal expression in normal tissues.
  • Anti-GFRA1-vcMMAE ADC demonstrated target-dependent cell killing and internalized to lysosomes.
  • Showcased robust therapeutic activity in preclinical xenograft models and favorable pharmacokinetic profiles in multiple species.

Conclusions:

  • Anti-GFRA1-vcMMAE ADC exhibits potent anti-tumor activity and a favorable safety profile in preclinical studies.
  • These findings suggest that anti-GFRA1-vcMMAE ADC represents a promising targeted therapeutic strategy for Luminal A breast cancer.

More Related Videos

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer10:36

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer

Published on: March 17, 2016

11.0K
Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells16:24

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells

Published on: February 21, 2014

20.7K

Related Concept Videos

Intracellular Hormone Receptors01:08

Intracellular Hormone Receptors

Lipid-soluble hormones diffuse across the plasma and nuclear membrane of target cells to bind to their specific intracellular receptors. These receptors act as transcription factors that regulate gene expression and protein synthesis in the target cell
59.8K
Internal Receptors01:31

Internal Receptors

Many cellular signals are hydrophilic and therefore cannot pass through the plasma membrane. However, small or hydrophobic signaling molecules can cross the hydrophobic core of the plasma membrane and bind to internal, or intracellular, receptors that reside within the cell. Many mammalian steroid hormones use this mechanism of cell signaling, as does nitric oxide (NO) gas.
74.8K
Drug-Receptor Bonds01:25

Drug-Receptor Bonds

Drug-receptor bonds are formed through various chemical forces when drugs interact with target cells. Covalent bonds, strong and irreversible, are exemplified by DNA-alkylating anticancer agents that inhibit cell division. However, such irreversible drug binding lacks selectivity and can modify the DNA of the surrounding healthy cells. Covalent binding often contributes to tissue toxicity, as seen with chloroform and paracetamol metabolites binding to the liver, causing hepatotoxicity.
In...
4.8K
Drug-Receptor Interactions01:29

Drug-Receptor Interactions

Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
7.6K
G-protein Coupled Receptors01:21

G-protein Coupled Receptors

G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.
132.2K
Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
5.1K